While companies fear losing to competitors, a bigger deterrent for head-to-head trials is the absence of a clear regulatory pathway to use favorable data (e.g., faster onset) for label claims. This removes a key commercial incentive for running these informative but risky studies.

Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

Initially intended to fill a therapeutic void, the FDA's pathway for single-arm trials in BCG-unresponsive bladder cancer has led to numerous approvals. This success has created a new problem: a crowded market of expensive drugs with weak comparative data, making rational treatment selection difficult.

Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.

Clinicians face a strategic dilemma where using an ADC off-label for a patient with a low-expressing biomarker (e.g., TDXD for HER2 1+) could provide benefit but also render that patient ineligible for a future clinical trial of a potentially more effective ADC. This highlights a tension between immediate access and optimizing long-term treatment sequencing.

Physicians face a dilemma: using an ADC off-label for a patient with a weak biomarker (e.g., HER2 1+), as permitted by NCCN compendium listings, may provide some benefit. However, this prior exposure can disqualify the patient from future clinical trials for potentially more effective ADCs.

The approval of effective therapies like nirogacestat creates an ethical dilemma. For patients with progressing tumors, continuing to use a placebo arm in clinical trials may no longer be appropriate, challenging future research design for this rare disease.

The pace of new drug approvals in oncology means that established clinical trial control arms, often using older chemotherapies, may no longer represent the true standard of care. This discrepancy can deter patient enrollment and challenges trial designers to remain nimble and current.

As effective treatments like EV Pembro become the standard of care in oncology, it is no longer ethically feasible to conduct randomized trials for new "me-too" drugs against the outdated platinum chemotherapy standard in many markets. This severely limits development pathways for fast-follower drugs.